Patents Examined by Pancham Bakshi
  • Patent number: 11458204
    Abstract: Disclosed herein is a method for preparing a hyaluronan-drug conjugate. The method uses the ethyl cyano(hydroxyimino)acetate/diisopropylcarbodiimide coupling system in a homogeneous reaction phase, which unexpectedly improves the substitution rate and substitution efficiency of hyaluronan-drug conjugates for various drugs.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: October 4, 2022
    Assignee: Aihol Corporation
    Inventors: Szu-Yuan Lee, Ping-Shan Lai, Chih-An Lin
  • Patent number: 11458202
    Abstract: The polysaccharide released from the unicellular cyanobacterium Cyanothece sp. CCY 0110 exhibits low cytotoxicity and proves to be suitable for the delivery of macromolecules. The cyanobacterium extracellular polymer disclosed in the present subject-matter, namely a polysaccharide and more in particular an heteropolysaccharide, assembles with proteins into a new phase with gel-like behaviour and the release kinetics can be modulated (i.e., delayed) by adding divalent cations and/or also exhibits physical and chemical properties typical of a bioemulsifier or a bioflocculant.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: October 4, 2022
    Assignee: INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR—IBMC
    Inventors: Rita Gil Vasconcelos Mota, Paula Tamagnini, Luis Miguel Gales Pereira Pinto, José Pedro Santos Leite, Sara Isabel Macedo Bernardes Pereira
  • Patent number: 11447451
    Abstract: Novel non-nucleoside solid supports and phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one non-nucleosidic moiety conjugated to a ligand of practical interest and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said solid supports and phosphoramidite building blocks, preferably followed by removal of protecting groups to provide oligonucleotides conjugated to ligands of interest.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: September 20, 2022
    Assignee: AM Chemicals LLC
    Inventors: Andrei Pavel Guzaev, Vladimir Y. VVedenskiy, Khirud Gogoi
  • Patent number: 11447478
    Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: September 20, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Hans Hilpert, Roland Humm, Thorsten Muser, Christian Schnider, Roger Wermuth, Thomas Woltering
  • Patent number: 11434252
    Abstract: Hydridosilapyrroles and hydridosilaazapyrrole are a new class of heterocyclic compounds having a silicon bound to carbon and nitrogen atoms within the ring system and one or two hydrogen atoms on the silicon atom. The compounds have formula (I): in which R is a substituted or unsubstituted organic group and R? is an alkyl group. These compounds react with a variety of organic and inorganic hydroxyl groups by a ring-opening reaction and may be used to produce silicon nitride or silicon carbonitride films.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: September 6, 2022
    Assignee: GELEST, INC.
    Inventors: Barry C. Arkles, Youlin Pan, Fernando Jove
  • Patent number: 11433088
    Abstract: Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition comprising nicotinamide mononucleotide and a pharmaceutical excipient to a subject.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 6, 2022
    Assignee: The Regents of the University of Colorado, A Body Corporate
    Inventors: Douglas R. Seals, Lindsey Gano, Natalie Poliektor
  • Patent number: 11426486
    Abstract: Provided herein are chitosan-containing formulations, methods of making such formulations, and methods of using such formulations. Chitosan contemplated for use herein is preferably of high quality and its source is preferably of crustacean origin. The formulations contemplated herein are aqueous, either liquid- or viscous-like, varying in concentration and type of chitosan and acid used, and may include other components. Their uses are diverse, for oral/dental administration or topical/surface application to subjects (e.g. humans or animals) in need thereof or even food commodities, aiming to maintain a good condition where it is applied or contributing to health enhancement, healing, disease prevention or treatment. The present invention also relates to concentrated solutions that may be used for the formulation of other products.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: August 30, 2022
    Assignee: Primex EHF.
    Inventors: Rúnar Marteinsson, Hélène L. Lauzon, Sigrídur Vigdís Vigfúsdóttir
  • Patent number: 11426420
    Abstract: A method of treating preventing, minimizing, and/or reversing congestive heart failure, cardiomyopathy, and/or reduction of cardiac ejection fraction in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: August 30, 2022
    Assignees: CASE WESTERN RESERVE UNIVERSITY, BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Sanford Markowitz, Won Jin Ho, Yiyuan Yuan, Mukesh Jain, Mohamed Sabeh, Joseph Ready, Noelle Williams
  • Patent number: 11420994
    Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: August 23, 2022
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Binghe Wang, Xingyue Ji, Zhixiang Pan
  • Patent number: 11419838
    Abstract: Compositions contain citrulline and leucine or a metabolite thereof including, for example, a synergistic amount of citrulline and leucine. Such compositions may be used in methods for the treatment of pre-diabetes, metabolic syndrome, hyperglycemia, or diabetes.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: August 23, 2022
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Christophe Moinard, Gabrielle Ventura, Denis Breuille, Christian Darimont-Nicolau, Luc Cynober
  • Patent number: 11401272
    Abstract: The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: August 2, 2022
    Assignee: Incyte Corporation
    Inventors: Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
  • Patent number: 11401290
    Abstract: The present invention relates to a vapor deposition compound enabling thin-film deposition through vapor deposition, and more particularly to a novel cobalt precursor, which can be applied to atomic layer deposition (ALD) or chemical vapor deposition (CVD) and exhibits superior reactivity, volatility and thermal stability, a method of preparing the same and a method of manufacturing a thin film using the same.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: August 2, 2022
    Assignee: HANSOL CHEMICAL CO., LTD.
    Inventors: Jung-Woo Park, Jang-Hyeon Seok, Hyo-Suk Kim, Ming-Sung Park
  • Patent number: 11400107
    Abstract: Provided are medical uses and methods for targeting cancer stem cells employing ProTide compounds, particularly in the prevention or treatment of cancer. The ProTide may be other than one selected from the group consisting of NUC-1031, a ProTide derived from cordycepin, and a ProTide derived from 8-chloroadenosine. The medical uses and methods for targeting cancer stem cells are particularly useful in the treatment of relapsed or refractory cancer in human patients. Also provided are methods of selecting patients who will benefit from prevention or treatment of cancer through the medical uses or methods of treatment of the invention.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: August 2, 2022
    Assignee: NuCana plc
    Inventors: Hugh Griffith, Chris Pepper, Chris McGuigan
  • Patent number: 11395849
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these N serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: July 26, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • Patent number: 11389466
    Abstract: Disclosed is a compound bearing at least two fucose moieties for its use as a drug in the prevention or treatment of infections caused by Aspergillus spp, the compound having a molecular weight included from 0.6 to 340 kDa, in particular from 0.6 to 2 kDa or from 1 to 7 kDa or from 2 to 10 kDa or from 5 to 340 kDa.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: July 19, 2022
    Assignees: UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Sébastien Gouin, Sami Brument, Annabelle Varrot, Patrice Lepape
  • Patent number: 11389540
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: July 19, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui
  • Patent number: 11390694
    Abstract: A gellan gum product having double setting temperatures, its preparation method and use thereof are provided.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: July 19, 2022
    Assignee: DSM IP ASSETS B.V.
    Inventors: Chienkuo Yuan, Jie Zhao, Guojun Liu
  • Patent number: 11389468
    Abstract: Provided herein are methods and compositions related to treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: July 19, 2022
    Assignee: Elysium Health, Inc.
    Inventors: Ryan Dellinger, Santiago Roel Santos, Eric Marcotulli, Daniel A. Alminana, Mark Morris, Leonard Pershing Guarente
  • Patent number: 11377455
    Abstract: A (meth)acryloyloxy-containing organosilicon compound (3) is prepared by simultaneously feeding a hydrohalosilane compound (1) and a (meth)acrylate compound (2) in the presence of a polymerization inhibitor to a reaction system, and effecting hydrosilylation reaction in the presence of a platinum catalyst. The content of (meth)acrylate compound (2) is 0-100 mol % based on the content of organosilicon compound (3) in the reaction system. R1 is a C1-C10 monovalent hydrocarbon group, X is halogen, n is 1, 2 or 3, R2 is H or methyl, and R3 is a C1-C18 alkylene group.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: July 5, 2022
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventor: Takeshi Nyuugaku
  • Patent number: 11376270
    Abstract: Compositions comprising decitabine and tetrahydrouridine or 5-azacytidine and tetrahydrouridine for the treatment of cancer are disclosed. The compositions in the form of a pill is administered to a human subject sequentially or alternately guided by the measurement of predictive biomarkers.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 5, 2022
    Assignee: EPIDESTINY, INC.
    Inventors: Yogen Saunthararajah, Joseph Desimone, Henry Lau, Santhosh Vadivelu